Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TDP1 | Q9NUW8 | 12/20 | 0.46 |
| ▸ | MAPT | P10636 | 12/20 | 0.46 |
| ▸ | KDM4E | B2RXH2 | 10/20 | 0.46 |
| ▸ | RECQL | P46063 | 7/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 6/20 | 0.46 |
| ▸ | BLM | P54132 | 6/20 | 0.46 |
| ▸ | LMNA | P02545 | 5/20 | 0.46 |
| ▸ | TSHR | P16473 | 5/20 | 0.46 |
| ▸ | HSD17B10 | Q99714 | 5/20 | 0.46 |
| ▸ | MTOR | P42345 | 4/20 | 0.46 |
| ▸ | HIF1A | Q16665 | 4/20 | 0.46 |
| ▸ | POLB | P06746 | 4/20 | 0.46 |
| ▸ | APEX1 | P27695 | 4/20 | 0.46 |
| ▸ | NFKB1 | P19838 | 3/20 | 0.46 |
| ▸ | ALOX15 | P16050 | 2/20 | 0.46 |
| ▸ | THPO | P40225 | 1/20 | 0.46 |
| ▸ | ADRB2 | P07550 | 6/20 | 0.45 |
| ▸ | ADRB1 | P08588 | 5/20 | 0.45 |
| ▸ | MAPK1 | P28482 | 5/20 | 0.45 |
| ▸ | MEN1 | O00255 | 5/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6346991 | 0.83 | TDP1 (0.51) | TDP1MAPTKDM4ERECQLKMT2A | |
| SCHEMBL21198878 | 0.80 | TDP1 (0.45) | TDP1MAPTKDM4ERECQLKMT2A | |
| SCHEMBL6340363 | 0.78 | TDP1 (0.43) | TDP1MAPTKDM4ERECQLKMT2A | |
| SCHEMBL3647916 | 0.77 | ACHE (0.47) | LMNAPOLBHPGDALDH1A1CYP2C19 | |
| SCHEMBL29430086 | 0.77 | TDP1 (0.53) | TDP1MAPTKDM4ERECQLKMT2A | |
| SCHEMBL28241555 | 0.77 | TDP1 (0.53) | TDP1MAPTKDM4ERECQLKMT2A | |
| SCHEMBL3642653 | 0.76 | FFAR2 (0.50) | KMT2ABLMLMNATSHRPOLB | |
| SCHEMBL8502013 | 0.75 | TDP1 (0.56) | TDP1MAPTKDM4ERECQLKMT2A | |
| Hydrochloric Acid SCHEMBL10340416 | 0.75 | KDM4E (0.55) | TDP1MAPTKDM4ERECQLKMT2A | |
| SCHEMBL3036448 | 0.75 | EPHX1 (0.59) | LMNAHSD17B10CYP1A2ALDH1A1CYP2C19 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20050080260-A1 | Preparation of prodrugs for selective drug delivery | LUMINIDE | 2005-04-14 | — | — | US | claimed |
| US-20050080260-A1 | Preparation of prodrugs for selective drug delivery | LUMINIDE | 2005-04-14 | — | — | US | disclosed |
| US-6555663-B1 | Pharmaceuticals which are activated intracellularly by reaction with cellular electron carriers or free radicals to cause release of a free and active drug molecule | MILLS RANDELL LEE (US) | 2003-04-29 | — | — | US | disclosed |
| EP-0414730-B1 | Chemical Compounds and pharmaceutical compositions capable of releasing a drug | MILLS RANDELL L (US) | 1999-12-15 | — | — | EP | disclosed |
| US-5773592-A | COMPRISES A CHEMILUMINESCENT MOIETY, A PHOTOCHROMIC MOIETY AND A BIOLOGICALLY ACTIVE AGENT CAPABLE OF BEING RELEASED | MILLS RANDELL LEE (US) | 1998-06-30 | — | — | US | disclosed |
| US-5428163-A | Luminides; chemiluminescence; redox system, releasing free drug | MILLS RANDELL L (US) | 1995-06-27 | — | — | US | disclosed |
| EP-0414730-A4 | LUMINIDE AND MACROLUMINIDE CLASS OF PHARMACEUTICALS | — | 1993-06-16 | — | — | EP | disclosed |
| EP-0414730-A1 | LUMINIDE AND MACROLUMINIDE CLASS OF PHARMACEUTICALS | Mills, Randell L. (US) | 1991-03-06 | — | — | EP | disclosed |
| WO-1989009833-A1 | LUMINIDE AND MACROLUMINIDE CLASS OF PHARMACEUTICALS | MILLS RANDELL L (US) | 1989-10-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050080260-A1 | Preparation of prodrugs for selective drug delivery | APEH, PAH, ALAD | TDP1 2098/4885MAPT 2279/4885KDM4E 3072/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.